Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 12/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156506 | 0.82 | CACNA1B (0.61) | CACNA1BPTGS2PTGS1MEN1KMT2A | |
| SCHEMBL5154821 | 0.82 | CACNA1B (0.51) | CACNA1BHTR7MEN1KMT2A | |
| SCHEMBL6824164 | 0.79 | CACNA1B (1.00) | CACNA1B | |
| SCHEMBL6823661 | 0.78 | CACNA1B (0.80) | CACNA1B | |
| SCHEMBL5156203 | 0.78 | PTGS2 (0.50) | CACNA1BHTR7PTGS2PTGS1 | |
| SCHEMBL5152223 | 0.78 | PTGS2 (0.50) | CACNA1BHTR7PTGS2PTGS1MEN1 | |
| SCHEMBL5156308 | 0.76 | CACNA1B (0.59) | CACNA1BMEN1KMT2A | |
| SCHEMBL5151377 | 0.75 | HCRTR1 (0.49) | CACNA1B | |
| SCHEMBL5156842 | 0.74 | CACNA1B (0.52) | CACNA1BPTGS2PTGS1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6820404 | 0.73 | CACNA1B (0.55) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004017965-A1 | 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN | IONIX PHARMACEUTICALS LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | CACNA1B 13/4885HTR7 1424/4885PTGS2 179/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | CACNA1B 10/4885HTR7 2363/4885PTGS2 697/4885 |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | CACNA1B 10/4885HTR7 2363/4885PTGS2 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.